Understanding Heart Damage from Doxorubicin Chemotherapy
Official title: Role of oxidative stress in doxorubicin-induced cardiotoxicity
Funded at Louisiana State Univ Hsc Shreveport · NIH-11143034 · Data updated 2026-11-12
This research explores why some patients experience heart damage from doxorubicin chemotherapy while others don't, focusing on individual genetic differences.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Louisiana State Univ Hsc Shreveport NIH-funded |
| Lab location | 1 site (Shreveport, United States) |
| Project start | February 1, 2018 |
| Project end | June 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $219,000 |
| NIH project number | 5P20GM121307-08 |
| Project ID | NIH-11143034 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients who have received doxorubicin chemotherapy or are considering it, especially those concerned about heart side effects, may find this research relevant.
✕Less likely to help
Patients not receiving doxorubicin chemotherapy or those without concerns about its cardiac side effects may not directly benefit from this specific research.
What this research studies
Doxorubicin is a powerful chemotherapy drug, but it can sometimes harm the heart. We know that people react differently to this drug, and their genes play a big part in how severe any heart damage might be. This project looks into how a process called oxidative stress, which is also influenced by your genes, contributes to this heart damage. We are specifically interested in a newly identified genetic area that might control how much oxidative stress occurs in heart cells.
Why it matters
Potential benefit: If successful, this work could help doctors predict which patients are at higher risk for heart damage from doxorubicin and potentially lead to ways to prevent it.
How similar studies have gone: While the general link between doxorubicin and cardiotoxicity is known, this research explores a novel genetic locus and its role in oxidative stress, building on preliminary data.
Where this research is happening
-
Louisiana State Univ Hsc Shreveport
Shreveport, United States Active
Researchers
- Principal investigator: Mohamed, Tarek Magdy — Louisiana State Univ Hsc Shreveport
- Study coordinator: Mohamed, Tarek Magdy
Related research
Other NIH-funded projects on the same topics.
-
Understanding why some patients have heart damage from doxorubicin and how to predict it
This grant looks at why doxorubicin can damage the heart in some patients and how genetic differences, especially related to oxidative stress, might help predict who is at higher risk.
-
Investigating how oxidative stress affects heart damage from doxorubicin in different racial groups
This study is looking into why African Americans may have more heart problems from the cancer drug doxorubicin than White Americans, by exploring how a specific gene and oxidative stress affect heart cells, using samples from both groups to find out what makes their responses different.
-
Dual targeting of heart cell receptors to prevent chemotherapy heart damage
Atrial patients receiving the chemotherapy drug doxorubicin may be protected from heart damage by targeting two heart cell receptors at once.
-
How vitamin B12 helps the gum-disease bacterium survive
Learning how vitamin B12 helps the bacteria that cause gum disease survive and become more harmful for people with periodontitis.
-
Genetic clues for doxorubicin heart risk using patient-derived heart cells
A research project tests how human heart cells grown from stem cells react to a common chemotherapy to see which genetic differences may raise the risk of heart damage.
-
Targeting STK3 to protect the heart during breast cancer treatment
A new approach tests whether blocking STK3 can protect the heart from chemotherapy damage without reducing its cancer-fighting effect in breast cancer patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.